1. Home
  2. SLN vs HPF Comparison

SLN vs HPF Comparison

Compare SLN & HPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • HPF
  • Stock Information
  • Founded
  • SLN 1994
  • HPF 2002
  • Country
  • SLN United Kingdom
  • HPF United States
  • Employees
  • SLN N/A
  • HPF N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • HPF Finance Companies
  • Sector
  • SLN Health Care
  • HPF Finance
  • Exchange
  • SLN Nasdaq
  • HPF Nasdaq
  • Market Cap
  • SLN 299.4M
  • HPF 341.3M
  • IPO Year
  • SLN N/A
  • HPF N/A
  • Fundamental
  • Price
  • SLN $5.04
  • HPF $16.11
  • Analyst Decision
  • SLN Buy
  • HPF
  • Analyst Count
  • SLN 5
  • HPF 0
  • Target Price
  • SLN $32.60
  • HPF N/A
  • AVG Volume (30 Days)
  • SLN 77.4K
  • HPF 35.3K
  • Earning Date
  • SLN 08-07-2025
  • HPF 01-01-0001
  • Dividend Yield
  • SLN N/A
  • HPF 8.96%
  • EPS Growth
  • SLN N/A
  • HPF N/A
  • EPS
  • SLN N/A
  • HPF N/A
  • Revenue
  • SLN $27,169,000.00
  • HPF N/A
  • Revenue This Year
  • SLN N/A
  • HPF N/A
  • Revenue Next Year
  • SLN N/A
  • HPF N/A
  • P/E Ratio
  • SLN N/A
  • HPF N/A
  • Revenue Growth
  • SLN 20.09
  • HPF N/A
  • 52 Week Low
  • SLN $1.97
  • HPF $12.99
  • 52 Week High
  • SLN $20.48
  • HPF $16.80
  • Technical
  • Relative Strength Index (RSI)
  • SLN 33.31
  • HPF 60.50
  • Support Level
  • SLN $4.86
  • HPF $15.92
  • Resistance Level
  • SLN $6.40
  • HPF $16.18
  • Average True Range (ATR)
  • SLN 0.45
  • HPF 0.09
  • MACD
  • SLN -0.15
  • HPF 0.03
  • Stochastic Oscillator
  • SLN 10.92
  • HPF 81.54

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About HPF John Hancock Pfd Income Fund II Pfd Income Fund II

John Hancock Preferred Income Fund II is the United States based closed-end, diversified management investment company. Its primary objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. The fund's principal investment strategies include to invests a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, capital preferred securities and short-term investments.

Share on Social Networks: